Objective
The goal of this project is to develop a novel ultra-rapid insulin (URI) that serves as a critical component for automated insulin delivery during meals.
Background Rationale
Currently, both rapid-acting and ultra-rapid insulin analogs, whether clinically approved or under development, cannot match the speed of natural insulin in onset, peak, and duration. As a result, even when integrated into automated insulin delivery systems, users must still manually input insulin doses for meals. There is an urgent need for a novel ultra-rapid insulin (URI) that offers significantly faster absorption to achieve full automation of meal-time insulin delivery, similar to the function of a pancreas.
Description of Project
Current rapid-acting insulin analogs still fall short of matching the speed of endogenous insulin in terms of onset, peak, and duration of action. Even when used with automated insulin delivery systems, users must still manually manage insulin dosing at mealtimes. This project aims to develop and validate a novel ultra-rapid insulin (URI) in animal studies. The proposed URI is expected to dramatically increase the speed of insulin action and, when paired with advanced precision algorithms, enable fully automated meal-time insulin delivery, mimicking the function of a pancreas. This advancement could significantly improve glycemic control and reduce the burden on patients managing Type 1 Diabetes (T1D).
Anticipated Outcome
By overcoming these technical limitations, the project aims to develop a URI that outperforms existing technologies. The new URI will enable fully automated insulin delivery at meals, alleviating the burden on patients and simplifying T1D management.
Relevance to T1D
The proposed URI, when incorporated into a fully automated insulin delivery system, is expected to improve glycemic control, enhance safety, and significantly reduce the daily management burden for T1D patients.